Table 7.

Antiviral treatment of HCV+ patients by DOPPS country and phase (1996–2015)

Region/CountryDOPPS Phasea
12345
Australia/New Zealand0 (27)0 (17)0 (26)1 (16)
Belgium0 (43)0 (27)1 (31)1 (26)
Canada0 (26)1 (29)0 (24)2 (31)
China1 (102)1 (58)
France4 (112)0 (84)3 (66)1 (44)1 (6)
Gulf Cooperation Council4 (113)
Germany0 (32)1 (26)3 (25)3 (21)1 (41)
Italy1 (154)1 (139)2 (99)0 (76)2 (60)
Japan0 (498)0 (288)0 (276)1 (188)2 (208)
Russia0 (46)
Spain0 (152)2 (92)4 (74)3 (82)2 (84)
Sweden1 (33)1 (32)1 (35)2 (41)
Turkey0 (11)
United Kingdom0 (15)1 (13)0 (6)1 (17)0 (20)
United States16 (618)0 (218)2 (136)4 (297)2 (252)
All DOPPS countries21 (1581)6 (989)16 (787)16 (943)21 (1013)
  • Expressed as n treated at enrollment or during follow-up (N HCV+ patients at enrollment); antiviral treatment defined as IFN, ribavirin, or new oral direct Hepatitis C virus inhibitor prescription; medications collected every 4 months in DOPPS phases 1, 3–5, and once yearly in DOPPS phase 2. HCV+, hepatitis C virus-positive; DOPPS, Dialysis Outcomes and Practice Patterns Study; —, not yet joined DOPPS.

  • a DOPPS phase 1 (1996–2001 in the United States, 1998–2001 in Europe/Japan); phase 2 (2002–2004); phase 3 (2005–2008); phase 4 (2009–2011); phase 5 (2012–2015).